To investigate the cytotoxic activity of BCL2 and BCR-ABL1 kinase inhibition, we exposed CP-CML CD34-positive progenitors to Venetoclax and Nilotinib or their combination for 24 h (Figure 1). Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.